Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. (Q54030746)

23 May 2018

title

Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. (English)

1 reference

23 May 2018

author

Harrison W Farber

series ordinal

2

1 reference

23 May 2018

author name string

Aguilar RV

series ordinal

1

1 reference

23 May 2018

language of work or name

English

0 references

publication date

1 November 2000

1 reference

23 May 2018

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

23 May 2018

volume

162

1 reference

23 May 2018

issue

5

1 reference

23 May 2018

page(s)

1846-1850

1 reference

23 May 2018

Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy

cites work

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Primary pulmonary hypertension associated with human immunodeficiency viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Primary pulmonary hypertension in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Pulmonary hypertension and human immunodeficiency virus infection. Two reports and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Role of prostacyclin in the treatment of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Primary pulmonary hypertension. A national prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.5.2004042

10.1164/AJRCCM.162.5.2004042

21 January 2018

Identifiers

DOI

1 reference

23 May 2018

1 reference

23 May 2018